Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Global, Survey

Accelerating study start-up is a top priority for life sciences companies according to the Veeva 2020 Study Start-up Pulse Report & Assessing Post-COVID Readiness, a global study start-up survey of more than 500 clinical operations professionals.

23.07.2020 - 11:02:56

Global Survey Reveals Urgency to Accelerate Study Start-up. Findings from Veeva Systems (NYSE: VEEV) show an industrywide shift to streamline study activation and speed clinical trials.

under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

@ businesswire.com